Opendata, web and dolomites

NanoSil4Cancer

Smart Multifunctional silica-based Nanoparticles for Targeted Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NanoSil4Cancer project word cloud

Explore the words cloud of the NanoSil4Cancer project. It provides you a very rough idea of what is the project "NanoSil4Cancer" about.

folate    intracellular    feasibility    chemotherapy    competence    environmental    cancer    communication    internalized    patients    customers    dramatically    cells    big    ep06745236    proprietary    healthcare    lowering    depends    accelerate    search    epo    interests    nanosil4cancer    antitumor    pct    nanoparticles    bortezomib    nevertheless    compartments    minimizing    efficacy    market    acquire    active    device    agents    overexpressing    therapeutic    90    290b    folic    technologies    therapy    minimize    platform    pharma    adherence    optimized    molecules    mesoporous    drug    released    individuate    stakeholder    sme    report    fr    13511    buy    business    marketing    release    normal    prototypes    prototype    ph    smart    dosage    sectorial    innovative    nano    sensitive    formulated    trend    patent    strategical    thomson    sparing    pro    silica    saving    customer    attractiveness    drugs    vehicles    missing    final    toxicity    receptor    acid    nanotechnologies    limited    medical    commercial   

Project "NanoSil4Cancer" data sheet

The following table provides information about the project.

Coordinator
NANOSILICAL DEVICES SRL 

Organization address
address: VIA PIETRO BUCCI CUBO 44A
city: RENDE
postcode: 87036
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.nanosilicaldevices.com/it/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2017-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NANOSILICAL DEVICES SRL IT (RENDE) coordinator 50˙000.00

Map

 Project objective

NanoSil4Cancer project will be able to accelerate the uptake of nanotechnologies, by developing, mesoporous silica-based prototypes of nano-vehicles, according to an innovative and proprietary approach (EP06745236), active in smart chemotherapy. This is aimed to minimize toxicity and the side effects of the traditional antitumor agents and to increase their therapeutic potential. This technology platform enables customers’ molecules to be formulated as pH–sensitive pro-drugs and introduced in smart nanoparticles able to reach the intracellular compartments of cancer cells where the drug is released. Development of new prototypes will lead to new patent applications. Recently we have developed and optimized a device, provided with folic acid, able to manage bortezomib release in cancer cells overexpressing folate receptor, FR (PCT-13511). The nanoparticles are only recognized and internalized by FR overexpressing cancer cells, where they release the drug, sparing normal cells. Nevertheless, our technology is general, not limited to a specific prototype, but depends on customer's needs, market and final users' needs. The feasibility study will individuate strategical market interests to address the prototypes production as business opportunities for our SME. Market trend and the role of Big Pharma will be defined to identify commercial partners and stakeholder to be involved in the project. We will buy sectorial report, we will use patent search such as EPO and Thomson, we will acquire missing competence in marketing and communication. The approach will represent a strong step forward in chemotherapy, improving the efficacy, lowering drug dosage (thus minimizing side effects for cancer patients and environmental impact), other than dramatically lowering EU Healthcare costs (up to 80-90% saving on non-adherence to the therapy costs, estimated in $290B/year), allowing Europe to increase its attractiveness in the field of innovative medical technologies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANOSIL4CANCER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NANOSIL4CANCER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More